Reducing Treatment Doses in Head and Neck Cancer to Improve QOL

Video

In this video we discuss efforts to reduce treatment doses in order to lessen long-term side effects and improve quality of life among patients with head and neck cancers.

In this video, Barbara Burtness, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses efforts to reduce treatment doses in order to lessen long-term side effects and improve quality of life (QOL) among patients with head and neck cancers.

One of the studies she discusses was recently published in the Journal of Clinical Oncology and showed that a subgroup of patients with human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma who were treated at a reduced radiation dose (≤ 54 Gy) had reduced side effects, with fewer patients having difficulty swallowing solid food (40% vs 89%; P = .011) or impaired nutrition (10% vs 44%; P = .025).

Recent Videos
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
head and neck cancer
head and neck cancer
head and neck cancer
Related Content